Donald A. Bergstrom
President of Research & DevelopmentDr. Donald A. Bergstrom, also known as Don, M.D., Ph.D., serves as Independent Director at Cellectis S.A. since September 2022 and was its Director since June 28, 2022 until September 2022 and served as its Board Observer since November 4, 2021 until June 28, 2022. Dr. Bergstrom serves as President of Research & Development at Relay Therapeutics, Inc. since January 2022. He served as Executive Vice President and Head of Research & Development at Relay Therapeutics, Inc. since April 2018 until January 2022. Dr. Bergstrom serves as an Independent Director at Fusion Pharmaceuticals Inc since April 01, 2021. Dr. Bergstrom joins at Relay Therapeutics, Inc. since April 2018. Dr. Bergstrom served as Global Head of Translational Medicine at Sanofi Genzyme, Oncology from May 2010 to January 2014. He was Chief Medical Officer of Mersana Therapeutics, Inc. from January 2014 to March 31, 2018 where he led the advancement of two products based on Mersana’s proprietary antibody-drug conjugate platform through non-clinical development and into Phase 1 clinical trials and was its Senior Vice President till March 31, 2018. Dr. Bergstrom joined Mersana after serving since May 2010 as Global Head of Translational and Experimental Medicine at Sanofi Oncology, where he led a team of laboratory and clinical scientists who integrated translational science into oncology drug development. From 2004 to 2010, Dr. Bergstrom held roles of increasing responsibility at Merck Research Laboratories, culminating in his role as Oncology Franchise Lead, Experimental Medicine. Prior roles at Merck included positions in Oncology Clinical Research and Clinical Molecular Profiling. He was the President in clinical pathology at the University of Washington. He has many years of experience in the biopharmaceutical and medical industries. Dr. Bergstrom received a B.A. in biophysics from The Johns Hopkins University. Dr. Bergstrom received M.D. and a Ph.D. from the University of Washington, Seattle and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed post-doctoral training both in Pathology. He was a resident in clinical pathology at the University of Washington.
Positions
- Company NameRelay Therapeutics, Inc.Stock CodeRLAYPositionPresident of Research & Development
